^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Ampulla of Vater Carcinoma
    Drug:Lumakras (sotorasib) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/13/2023
    Excerpt:
    Ampullary Adenocarcinoma: Useful in Certain Circumstances...Sotorasib (if KRAS G12C mutation positive)...
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

    Excerpt:
    Amgen...announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC) that has progressed after systemic anticancer therapy.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

    Published date:
    11/17/2020
    Excerpt:
    This study evaluates AMG 510 in pts with locally-advanced or metastatic KRAS p.G12C mutant solid tumors….best overall responses were...13 stable disease (6 pancreatic, 2 appendiceal, 1 ampullary, 1 bile duct, 1 endometrial, 1 sinonasal, and 1 unknown primary)...AMG 510 was well tolerated and demonstrated clinical activity in pts with advanced KRAS p.G12C mutant solid tumors other than NSCLC and CRC.
    DOI:
    10.1200/JCO.2020.38.15_suppl.3511
    Trial ID:
    CodeBreak 100